The enhancement of FGL1 levels was regulated by IL-6 [20, 21] and it participates in the development of non-alcoholic fatty liver disease, hepatocellular carcinomas, and hepatocyte mitogenic activity [22–26]. This evidence concerns the gene FGL1 and metabolic dysfunction-associated steatotic liver disease.